Yasunori Kaneko Biography and Net Worth

Director of Arcus Biosciences

Dr Kaneko has served as a member of our board of directors since May 2015. Dr Kaneko has been a managing director at Skyline Venture Partners, a venture capital firm, since 1999. Previously, Dr Kaneko served on the board of LeukoSite, a biopharmaceutical company, until its merger with Millennium Pharmaceuticals in 1999. Dr Kaneko also served as CFO and Vice President, Business Development at Tularik, a biopharmaceutical company, from 1992 until 1998. Dr Kaneko served as a Senior Vice President and CFO of Ionis Pharmaceuticals, a biopharmaceutical company, which went public in May 1991 during his tenure. Dr Kaneko began his career at Genentech, where he served in a business development role, a biotechnology company, and as head of corporate finance in the investment banking division of Paribas Capital Markets LTD in Tokyo.

Dr Kaneko received an undergraduate degree and an MD degree from Keio University in Tokyo, and an MBA from Stanford Business School. He currently serves as a member of the Dean of Research Advisory Council at Stanford University.

What is Yasunori Kaneko's net worth?: The estimated net worth of Yasunori Kaneko is at least $238,702.00 as of February 27th, 2025. Dr. Kaneko owns 28,400 shares of Arcus Biosciences stock worth more than $238,702 as of April 25th. This net worth approximation does not reflect any other investments that Dr. Kaneko may own. Learn More about Yasunori Kaneko's net worth.
How do I contact Yasunori Kaneko?: The corporate mailing address for Dr. Kaneko and other Arcus Biosciences executives is 3928 Point Eden Way, Hayward CA, 94545. Arcus Biosciences can also be reached via phone at (510) 694-6200 and via email at investorinfo@arcusbio.com. Learn More on Yasunori Kaneko's contact information.
Has Yasunori Kaneko been buying or selling shares of Arcus Biosciences?: Yasunori Kaneko has not been actively trading shares of Arcus Biosciences during the last ninety days. Most recently, on Thursday, February 27th, Yasunori Kaneko bought 20,000 shares of Arcus Biosciences stock. The stock was acquired at an average cost of $10.06 per share, with a total value of $201,200.00. Following the completion of the transaction, the director now directly owns 28,400 shares of the company's stock, valued at $285,704. Learn More on Yasunori Kaneko's trading history.
Who are Arcus Biosciences' active insiders?: Arcus Biosciences' insider roster includes Robert Goeltz II (CFO), Juan Jaen (President), Jennifer Jarrett (COO), Yasunori Kaneko (Director), Terry Rosen (CEO), and Carolyn Tang (General Counsel). Learn More on Arcus Biosciences' active insiders.
Are insiders buying or selling shares of Arcus Biosciences?: During the last twelve months, Arcus Biosciences insiders bought shares 2 times. They purchased a total of 39,800 shares worth more than $402,764.00. During the last twelve months, insiders at the sold shares 2 times. They sold a total of 3,795 shares worth more than $56,989.32. The most recent insider tranaction occured on February, 27th when Director Yasunori Kaneko bought 20,000 shares worth more than $201,200.00. Insiders at Arcus Biosciences own 12.3% of the company. Learn More about insider trades at Arcus Biosciences.
Information on this page was last updated on 2/27/2025.

Yasunori Kaneko Insider Trading History at Arcus Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/27/2025	Buy	20,000	$10.06	$201,200.00	28,400
4/23/2021	Buy	4,133	$31.37	$129,652.21	6,717

Yasunori Kaneko Buying and Selling Activity at Arcus Biosciences

Arcus Biosciences Company Overview

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Today's Range

Now: $8.41

$8.07

$8.48

50 Day Range

MA: $8.84

$6.87

$11.09

2 Week Range

Now: $8.41

$6.50

$18.98

Volume

859,431 shs

Average Volume

797,194 shs

Market Capitalization

$883.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.54